Figure 6 | Scientific Reports

Figure 6

From: A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications

Figure 6

Meta-analysis of sub-grouped Fluvoxamine/COVID-19 studies based on dose, up to 100, up to 200, and up to 300 mg/day. (A) Forrest plot. 100 mg/day LogOR 1.43 (95% CI -1.16 to 4.01) z = 1.082, p = 0.279. 200 mg/day LogOR 0.550 (95% CI 0.236 to 0.865) z = 3.433 p < 0.001. 300 mg/day LogOR 1.153 (95% CI 0.593 to 1.713) z = 4.035 p < 0.001 (B) Funnel plots. No Asymmetry was observed at dose grouping.

Back to article page